J Gynecol Oncol.  2009 Dec;20(4):201-202. 10.3802/jgo.2009.20.4.201.

Time for global efforts with clinical trials for advanced cervical cancer patients

• Chun M

• KMID: 2288581
• DOI: http://doi.org/10.3802/jgo.2009.20.4.201

Abstract

No abstract available.

MeSH Terms

Humans
Uterine Cervical Neoplasms

Reference

1. Aziz MF. Gynecological cancer in Indonesia. J Gynecol Oncol. 2009. 20:8–10.

2. Domingo EJ, Dy Echo AV. Epidemiology, prevention and treatment of cervical cancer in the Philippines. J Gynecol Oncol. 2009. 20:11–16.

3. Noh JM, Park W, Huh SJ, Cho EY, Choi YL, Lee JH, et al. Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma. J Gynecol Oncol. 2010. 20:215–220.

4. Verma AK, Arya AK, Kumar M, Kumar A, Gupta S, Sharma DN, et al. Weekly cisplatin or gemcitabine concomitant with radiation in management of locally advanced carcinoma cervix: results from an observational study. J Gynecol Oncol. 2010. 20:221–226.

5. Kim HJ, Ha SW, Wu H. Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy. J Gynecol Oncol. 2010. 20:227–232.

6. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol. 2009. 36:170–180.

7. Alvarez EA, Wolfson AH, Pearson JM, Crisp MP, Mendez LE, Lambrou NC, et al. A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer. Gynecol Oncol. 2009. 113:195–199.

8. del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol. 2008. 110:3 Suppl 2. S72–S76.

9. Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003. 55:16–20.

10. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res. 2004. 10:1366–1374.

11. Kim JS, Li S, Kim JM, Yeo SG, Kim KH, Cho MJ. Cyclooxygenase-2 expression as a predictor of para-aortic lymph node recurrence in uterine cervical cancer. Int J Radiat Oncol Biol Phys. 2008. 70:1516–1521.

12. Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A, et al. A prospective phase I-II trial of the cyclooxynase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2007. 67:97–103.

13. Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol. 2008. 109:140–145.

14. Walker JL, Morrison A, DiSilvestro P, von Gruenigen VE. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecol Oncol. 2009. 112:78–84.

15. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, et al. Cervical carcinoma metaststic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998. 42:1015–1023.